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Background: Although anti-endomysia l antibodies (EmA) have been found in the supernatant s of
cultured intestinal mucosa from patients with coeliac disease (CD), in no study has the clinical reliability
of this new diagnostic tool been investigated . Our aims were to evaluate the clinical usefulness of the in
vitro production of EmA in CD diagnosis in consecutiv e patients with suspected CD, and to evaluate the
reliability of the in vitro challenge in CD patients on a gluten-free diet (GFD). Methods: For the former
aim, consecutiv e patients who were due to undergo intestinal biopsy for suspected diagnosis of CD were
enrolled; according to the  nal diagnosis , these patients were divided into two groups: Group 1 comprised
91 newly diagnosed CD patients (40 males; age range 7 months to 84 years), Group 2 included 100
subjects with diseases other than CD (44 males; age range 9 months to 76 years). For the latter aim, we
also studied 21 CD patients on a gluten-free diet after 16–123 months (8 males; age range 3–51 years),
with normal intestinal architectur e (Group 3) and 22 patients who served as controls (12 males; age range
4–60 years) with gastroesophagea l re ux disease-lik e symptoms (Group 4). All patients underwent
determination of serum anti-gliadin (AGA) and EmA antibodies , histology evaluation of the intestinal
biopsies and EmA assay in the supernatant s of in vitro gliadin-challenge d duodenal mucosa. Results:
EmA assay in the supernatant s showed a sensitivity and speci city of 96% and 100%, respectively ; these
were not signi cantly different from those observed for serum EmA (88% and 99%, respectively) .
However, EmA assay in the supernatant s was useful in CD patients with mild intestinal histology lesions
(in ltrative/hyperplastic type): in this subgroup it was positive in 9/12 of cases, but serum EmA was
positive in only 2/12. As regards the reliability of the in vitro gliadin challenge, EmA production in
supernatant s was recorded only in 10/21 CD patients on a gluten-free diet. The patients with a positive in
vitro challenge had a higher number of intra-epithelia l lymphocytes than patients with a negative
challenge. Conclusions: 1) EmA assay in the medium of cultured intestinal biopsy can detect gluten-
sensitive enteropathy , characterized by an in ltrative/hyperplasti c histologica l pattern, which is often
associated with negative serum EmA. 2) The in vitro challenge in CD patients on a gluten-free diet
detects EmA production in the culture medium only in half of the cases and other studies must be
performed to evaluate whether EmA production after in vitro challenge can be considered a reliable test
for con rming CD diagnosis .
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During the past few decades there has been an increasein the number of coeliac disease (CD) diagnoses, andpopulation studies indicate a CD prevalence much
higher than previously reported (1, 2). Certainly, this phenom-
enon is in part due to the advances in diagnostic means. These
include the very recently described detection of anti-endomy-
sial antibodies (EmA) in in vitro cultured intestinal explants
from untreated CD patients and the opportunity to perform an
in vitro gliadin challenge (3), thus avoiding the complaints and
the psychological impact of the classical challenge. However,
few studies have evaluated this method and few patients have
undergone this new diagnostic test (3–5). Furthermore, the
possibility of performing the in vitro challenge—the in vitro
production of EmA by the duodenal mucosa of CD patients on
a gluten-free diet stimulated with gliadin in standard condi-
tions—has not always been con rmed (4). The present study
was performed to investigate the clinical usefulness of the in
vitro production of EmA in CD diagnosis in a large number of
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consecutive patients with suspected CD.We also evaluated the
reliability of the in vitro challenge in CD patients on a gluten-
free diet (GFD).
Patients and Methods
A total of 234 patients were included in the study, one part to
evaluate the diagnostic accuracy of serum and cultured EmA
assays, the other to evaluate the reliability of the in vitro
challenge.
Patients enrolled to evaluate EmA diagnostic accuracy in
sera and supernatants
We enrolled 191 consecutive patients, including both
children and adults, who had undergone intestinal biopsy
for suspected diagnosis of CD at the Division of Internal
Medicine of the University Hospital or at the Pediatric
Division of the ‘Di Cristina’ Hospital, both in Palermo,
between May 1998 and April 1999. The patients included
presented one or more of the following symptoms: poor
growth or weight loss (97 cases), anaemia (82 cases), chronic
diarrhoea (82 cases), abdominal pain (71 cases) alternating
bowel habits (61 cases), constipation (20 cases), vomiting (8
cases). Exclusion criteria were: (a) presence of clinical signs
or laboratory data which could indicate a diagnosis other than
CD as more probable (ESR >15, positivity of serum reactive
C protein, presence of blood in stools, fever); (b) a previous
serological or histological evaluation for suspected CD.
According to the  nal diagnosis, these patients were divided
into two groups: Group 1 comprised 91 newly-diagnosed CD
patients (40 males; age range 7 months to 84 years, median 2
years) and Group 2 included 100 subjects with normal
intestinal morphology (villi/crypts ratio >2.5–3 for children,
>3 for adult patients) and diseases other than CD (44 males;
age range 9 months to 76 years, median 21 years).
CD diagnosis in the Group 1 patients was based on the
evidence of clinical symptoms and intestinal histology
damage (in ammatory in ltration of the mucosa with en-
larged crypts and/or intestinal villous atrophy) on a gluten-
containing diet, disappearance of the symptoms and normal-
ization of the intestinal histology on a gluten-free diet and
reappearance of the symptoms on gluten-challenge. Table I
speci es the number of paediatric and adult patients recruited
and the  nal diagnoses of the control patients (Group 2).
Patients enrolled to evaluate the reliability of the in vitro
challenge
Two other patient groups were formed to evaluate the
reliability of the in vitro challenge in CD patients on a gluten-
free diet. Group 3 included 21 patients on a gluten-free diet
after 16–123 months (8 males; age range 3–51 years, median
5 years), with normal intestinal architecture; Group 4
included 22 patients who served as controls (12 males; age
range 4–60 years, median 33 years), with gastroesophageal
re ux disease-like symptoms (epigastric pain, regurgitation)
who underwent esophago-gastroscopy. These patients were
negative for serum EmA and anti-gliadin antibodies (both IgA
and IgG) and had a normal intestinal histology and no family
history of CD.
CD diagnosis in the Group 3 patients was based on the
criteria of the ESPGHAN (6). The patients of Group 4 were
found to have peptic esophagitis (18 cases) or gastric
erosions/ulcers (4 cases).
The protocol was approved by the ethics committee of the
‘Di Cristina’ Hospital of Palermo and informed consent was
obtained from adult patients or from the parents of the
children involved in the study.
Serum anti-gliadin (AGA) and anti-endomysial (EmA)
antibodies determination
Serum levels of both IgG and IgA AGAwere determined as
previously described (7), with a commercially available
enzyme-linked immunosorbent technique (Alpha-Gliatest,
Eurospital Pharma, Trieste, Italy). Results were expressed
as a percentage of reference serum; 20% was the upper
normal limit for IgG and 10% for IgA antibodies. These
values are equal to the mean § 2 s (standard deviation) of the
values obtained in our laboratory in a large group of age-
matched normal subjects.
IgA-class EmA values were determined with a commer-
cially available indirect immuno uorescence technique on
monkey oesophagus (Anti-endomisio, Eurospital Pharma,
Trieste, Italy), as previously described (8). IgA EmA titres
were semi-quanti ed as follows: 0 = not detectable, 1 = posi-
tive at dilutions between 1/5 and 1/20, 2 = positive between
1/40 and 1/80, 3 = positive at 1/100, 4 = positive at 1/200, 5 =
positive at dilutions >1/200. Total immunoglobulins (IgA,
IgM, IgG) were also measured by ELISA.
IgA anti-endomysial antibody determination after intestinal
mucosa in vitro culture
This test was performed in accordance with the method
described by Picarelli et al. (5), using a commercially
available kit (Antiendomysium-biopsy, Eurospital, Trieste,
Italy). Brie y, a specimen of small intestinal mucosa was
Table I. Number of paediatric and adult patients included in the
study and  nal diagnoses of the subjects considered as controls
No. of cases
Children 100
Coeliacs 60
Total controls 40
Multiple food intolerance 18
Irritable bowel syndrome 13
Intestinal giardiasis 9
Adults 91
Coeliacs 31
Total controls 60
Irritable bowel syndrome 57
Crohn disease 3
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incubated immediately after biopsy in a culture medium
for 48 h at 37 °C in the presence of the gliadin peptide
corresponding to the 31–43 (Leu-Gly-Gln-Gln-Pro-Phe-Pro-
Pro-Gln-Gln-Pro-Tyr) aminoacid sequence of -gliadin (1 mg/
ml). After incubation, EmAs were detected in the culture
supernatants, both undiluted and diluted 1:2, 1:4 and 1:8, and
40 ml of supernatant was applied to each section of monkey
oesophagus for 45 min according to the same procedure
followed for serum EmA determination. As for serum EmA,
titres in the supernatants were also semi-quanti ed as follows:
0 = not detectable, 1 = positive without any dilution, 2 =
positive at dilution 1:2, 3 = positive at 1:4, 4 = positive at
1:8, 5 = positive at dilutions >1:8.
These results were also blindly evaluated by two different
observers with experience in immuno uorescence assay.
Intestinal biopsy and histology
In the children, biopsy specimens were obtained distally to
the ligament of Treitz, with a multipurpose Crosby capsule
positioned under  uoroscopy, as previously described (9); in
the adults, biopsies were taken during gastroduodenoscopy. In
all cases, at least four biopsy specimens, each weighing about
80 mg, were taken; two mucosa fragments were immediately
incubated for in vitro study (one with and one without gliadin)
and the others were studied for histology. Specimens adequate
in size and orientation according to the criteria of Perera et al.
(10) were embedded in paraf n and slides were stained with
haematoxylin and eosin and graded by conventional histology
as follows: Normal, corresponding to normal villi/crypts ratio
and no evidence of enhanced in ammatory in ltrate; Grade I,
corresponding to in ltrative/hyperplastic lesions with normal
villi and enlarged crypts, associated with diffuse intraepithe-
lial in ammatory in ltration (types 1 and 2, according to
Marsh (11)); Grade II, corresponding to partial villous
atrophy with enlarged, deep crypts; and Grade III, corre-
sponding to total villous atrophy (type 3, according to Marsh
(11)). The severity of the intestinal mucosa damage was semi-
quanti ed as follows: 0 = normal mucosa; 1 = grade I lesions;
2 = grade II lesions; 3 = grade III lesions. Furthermore, the
number of intraepithelial lymphocytes (IELs) per 100 villous
epithelial cells was assessed as described by Ferguson et al.
(12). (The highest normal value in our laboratory is equal to
25 IELs per 100 epithelial cells.)
In all cases histology was described by an examiner
unaware of the clinical condition of the patients and of the
laboratory test results.
Statistical Analysis
The levels of sensitivity and speci city of the methods
examined were calculated by standard statistical methods
(13). Sensitivity was de ned as the ratio of the true positive to
true positive plus false-negative values; speci city was
de ned as the ratio of true negative to true negative plus
false-positive values. Spearman’s r correlation coef cient
was used to correlate serum EmA or culture EmA titres with
the degree of intestinal histology damage. The Wilcoxon rank
sum test was used to compare culture EmA titres without
and with 31–43 peptide incubation in patients with newly
diagnosed CD (Group 1). The Mann-Whitney U test was used
to compare the number of IELs per 100 villous epithelial cells
in CD patients on a gluten-free diet (Group 3). All data were
analysed considering both the whole study group and
separating children and adult patients. A P value <0.05 was
considered to be signi cant.
Results
EmA sensitivity and speci city in serum and supernatant
assay
Table II gives the results of serum AGA and EmA and of
intestinal mucosa EmA in vitro production in the 191
consecutive patients investigated for suspected CD (Group
1 plus Group 2), divided according to  nal diagnosis. As
expected, the serum EmA assay had a higher diagnostic
accuracy than the AGA assay: serum EmA were positive in
80/91 CD patients and in 1/100 gastrointestinal control (one
patient with Crohn disease with serum EmA titre of 1:20).
The false-negative results in CD (Group 1) were recorded in
one patient with selective de ciency of serum IgA and in 10
patients with slightly abnormal intestinal mucosa architecture
(villi/crypts ratio ranged between 3.1 and 2.5, with marked
crypt hypertrophy) and with intestinal histology characterized
by in ltration of lymphocytes and plasma cells in the lamina
propria and in the mucosa (Fig. 1). Their intra-epithelial
lymphocyte count ranged between 54 and 78 per 100
epithelial cells (in ltrative/hyperplastic lesion, Grade I
according to the ‘Methods’ de nition). Five of these patients
were adults (age range 20–70 years) and six children (age
range 2–13 years). They had one or more of the following
symptoms: chronic diarrhoea (3 cases), anaemia (4 cases),
poor growth (3 cases), abdominal pain (3 cases), and all
patients were found to have the classical DQ2 haplotype. In
all cases symptoms improved a few weeks after commence-
ment of a gluten-free diet and disappeared during the
following months. Furthermore, the intestinal biopsy per-
Table II. Number of patients positive for serum anti-gliadin (AGA
IgG and IgA), serum anti-endomysia l antibodies (serum EmA),
EmA antibodies in the culture medium without gliadin-peptid e
incubation (culture EmA) and with gliadin-peptid e incubation
(culture EmA‡ gliadin), in patients with suspected coeliac disease,
divided according to the  nal diagnosis: CD patients on gluten-
containing diet (Group 1) and patients with gastrointestina l diseases
other than celiac disease (Group 2)
Group 1 (n = 91) Group 2 (n = 100)
Serum AGA IgG 69/91 (76%) 25/100 (25%)
Serum AGA IgA 61/91 (67%) 10/100 (10%)
Serum EmA 80/91 (88%) 1/100 (1%)
Culture EmA 82/91 (90%) 0/100 (0%)
Culture EmA ‡ gliadin 87/91 (96%) 0/100 (0%)
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formed after 12 months on GFD showed a normal villi/crypts
ratio (values ranged between 3.5 and 4.8), without any
in ammatory in ltration in the lamina propria and in the
mucosa (IEL ranged between 11 and 21 per 100 epithelial
cells), while symptoms reappeared in all patients during a
subsequent gluten challenge. In the CD patients (Group 1), the
in vitro tests for EmA production without 31–43 peptide
incubation showed positive supernatants in 82/91 cases (all
the patients positive for serum EmA plus two of the patients
with the in ltrative/hyperplastic pattern of the intestinal
mucosa). After incubation of the intestinal biopsy samples
with the 31–43 peptide, EmA were positive in 87/91 cases. In
the latter experiment, apart from the subject with IgA
de ciency, only three CD patients were negative for EmA
in the culture medium. None of the subjects in Group 2
(patients with gastrointestinal diseases other than CD) showed
EmA positivity in the supernatants of cultured intestinal
mucosa, either with or without 31–43 peptide incubation.
Table III gives the sensitivity and speci city of the tests in the
whole study group and separately for children and adults. As
regards serum EmA sensitivity, it must be underlined that
there was a great difference between CD patients with slight
intestinal mucosa damage (Grade I histology) and CD patients
with partial or total intestinal villous atrophy (Grades II and
III). In fact, serum EmA were positive only in 2/12 CD
subjects with Grade I histology and in 78/79 CD patients with
Grade II/III histology. Thus, serum EmA sensitivity was
almost 100% in CD with severe intestinal lesions but only
17% in patients with mild mucosa damage. However, in the
latter subgroup of CD patients, EmA assay in the medium of
cultured intestinal mucosa with the addition of the 31–43
peptide was positive in 9/12 cases (Fig. 2). Furthermore,  ve
of the subjects negative for serum EmA but positive for
cultured EmA assay were also negative on serum anti-
transglutaminase assay with a commercial ELISA.
Concordance between the two observers in the evaluation
of EmA in culture medium results as ‘positive’ or ‘negative’
was 98%; EmA titre evaluation was also signi cantly con-
cordant (r = 0.96; P < 0.0001).
Further evidence of in vitro EmA production and relation-
ship with intestinal histology
In the 82/91 CD patients (Group 1) with EmA production in
the in vitro intestinal culture system without 31–43 peptide
incubation, EmA titres in the supernatants ranged from 1:1
(positivity only in the undiluted medium) to 1:8 with a median
value of 1:1; after in vitro incubation with the 31–43 peptide
the EmA titre increased over the baseline culture condition in
38/82 samples, whereas in the other 44 EmA titres were
Fig. 1. Aspect of the intestinal mucosa in one of the coeliac disease
patients with Grade I lesion histology (according to the Methods
de nition). Normal villi with lymphocyte in ltration (£50) can be
seen. This histology aspect was typical for all the studied cases
negative for serum EmA but positive for cultured EmA assay.
Table III. Sensitivity and speci city of the serologica l tests and the determination of in vitro EmA production by intestinal mucosa in the
diagnosis of coeliac disease. Consecutive patients with suspected CD were studied
Serum AGA
IgG
Serum AGA
IgA
Serum
EmA
Culture EmA
without gliadin
Culture EmA
with gliadin
All cases (n = 191)
Sensitivity 76% 67% 88% 90% 96%
Speci city 75% 90% 99% 100% 100%
Children (n = 100)
Sensitivity 88% 78% 87% 88% 95%
Speci city 75% 90% 100% 100% 100%
Adults
Sensitivity 52% 45% 90% 94% 97%
Speci city 75% 90% 98% 100% 100%
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unchanged: range titres 1:1 – >1:8, median 1:2 (Wilcoxon
rank sum test: z = 5.37; P < 0.0001) . No difference was
observed between children and adult CD patients as regards
the increase in EmA titre after incubation with the 31–43
peptide: there was a titre increase in 28/60 paediatric patients
and in 10/31 adults.
When EmA titres of the cultured intestinal mucosa with the
addition of the 31–43 peptide in the medium were analysed
according to the severity of intestinal mucosa damage, we
observed in CD patients on a gluten-containing diet (Group 1)
a signi cant positive correlation between EmA in vitro
production and the grade of histological mucosa damage
(r = 0.53; P < 0.0001). Serum EmA titres of CD patients also
positively correlated with severity of intestinal mucosa
damage but had a lower r value than EmA titres of the
medium culture: 0.42 (P < 0.001). The same trend was
observed in both the paediatric and adult CD patients.
Reliability of the in vitro challenge in CD patients on a
gluten-free diet
All but one of the 21 CD patients on GFD (Group 3) were
negative for serum EmA, but this subject admitted to
prolonged dietary lapses. EmA in the culture medium of
intestinal mucosa without 31–43 peptide addition were
positive only in this patient (at a titre of 1:1); he was an adult
with normal intestinal mucosa architecture (villi/crypts ratio
3.5) but with intense in ammatory in ltration of the mucosa
(IEL count = 54). When the intestinal mucosa of the CD
patients on GFD was incubated for 48 h with 31–43 peptide,
EmA production was observed in 10/21 culture media, at a
titre of 1:1 in all cases. Table IV gives some clinical and
histology characteristics in the patients with positive in vitro
challenge and in those with negative challenge. The
frequency of positive responses to this in vitro challenge
was related to a shorter duration of the gluten-free diet and a
higher IEL count. In contrast, none of the 22 controls (Group
4) was positive for EmA in the culture supernatants either
with or without gliadin-peptide addition.
Discussion
Recent evidence that the intestinal mucosa of CD patients is
the site of EmA production and that this could be stimulated
in treated CD patients by in vitro challenge with gliadin (3)
has opened interesting new perspectives both on the
pathogenesis and the diagnosis of CD. However, studies
published to date have included only a small number of CD
patients (39 and 11 cases, respectively, in two papers by
Picarelli et al. (3, 5), 36 in an Austrian study (4) and 7 in a
paper by Biagi et al. (14)) and have not evaluated whether this
new assay can improve diagnostic accuracy in patients with
clinical symptoms suggesting CD. Furthermore, the reliability
of the in vitro challenge is uncertain as, in contrast to the
Italian studies (3, 5), Vogelsang et al. never detected EmA in
vitro production after gliadin incubation in treated CD
patients. Thus we designed the present study to evaluate the
clinical usefulness of in vitro EmA production in CD
diagnosis, enrolling consecutive patients with symptoms
which led to a suspected CD diagnosis. The commercial kit
allows this assay to be performed in a very simple manner,
and it can readily be used in any laboratory where serum
EmAs are routinely assayed.
Our study demonstrates that, compared with serum EmA
determination, EmA determination in the medium of cultured
Fig. 2. Sensitivity of EmA determination in the serum and in the
supernatan t of cultured intestinal biopsies with addition of the 31–43
gliadin peptide in 91 coeliac disease subjects at diagnosis . The
patients were divided according to severity of intestinal mucosa
damage. Histology was graded as follows: Grade I, correspondin g to
in ltrative/hyperplasti c lesions with normal vili and enlarged crypts,
associated with diffuse intra-epithelia l in ammatory in ltration;
Grade II, corresponding to partial villous atrophy with enlarged,
deep crypts and Grade III, correspondin g to total villous atrophy. (&
Serum EmA; & cultured EmA).
Table IV. Sex, age, duration of the gluten-free diet, villi/crypts ratio and intra-epithelia l lymphocyte (IEL) count in 10 CD patients on gluten-
free diet who were positive at the in vitro challenge and in 11 CD patients who were negative. All values are expressed as range and median
Positive on in vitro
challenge
Negative on in vitro
challenge
Age (years) 3–51 (5) 4–42 (5)
Sex 4 M, 6 F 4 M, 7 F
Duration of the gluten-free diet (months) 16–48 (30)* 18–123 (48)*
Villi/crypts ratio 3.5–4 (3.6) 3.5–4.1 (3.6)
IEL count (£100 epithelia l cells) 18–41 (31)** 13–23 (18)**
* P< 0.005 (z = 2.8).
** P > 0.005 (z = 2.9).
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intestinal mucosa with the addition of the 31–43 gliadin-
peptide in general does not signi cantly improve diagnostic
accuracy in patients with suspectedCD.However, if our results
have con rmed (15, 16) that serum EmAs have a good
sensitivity and speci city in CD diagnosis (88% and 99%,
respectively, in the present whole study group), a very low
sensitivity was found in patients with mild intestinal mucosa
damage: 17% (2/12 patients). This concurs with previous
reports indicating that the development of serum EmA
positivity in CD depends on the severity of intestinal
histopathology (17, 18). Furthermore, a recent study by
Rostami et al. has shown that EmA sensitivity progressively
increases from 31% to 100% when CD patients with
progressively more severe intestinal mucosa damage are
considered (19). In this respect, our results show that EmA
assay on the medium of cultured intestinal mucosa is of great
usefulness. In fact, this test correctly identi ed another 7 CD
patients who were negative for serum EmA (the test was
positive in 9/12 CD subjects with in ltrative/hyperplastic
mucosa lesions). So, although if we consider the CD group
studied as a whole the increase in sensitivity between serum
EmA (88%) and cultured EmA (96%) assay is not statistically
signi cant, it is certainly impressive in CD subjects with
low-grade intestinal lesions (17% for serum EmA, 75% for
cultured EmA).
The size of the CD population with mild intestinal lesions is
unknown and this histology is probably frequent in subclinical
forms of CD. In our experience, the in ltrative histology
picture can be seen in approximately 10% of symptomatic
gluten-sensitive patients; furthermore, it is observed in about
40% of the patients with dermatitis herpetiformis (22).
Obviously, intestinal biopsy remains the gold standard for
CD diagnosis, but mild-moderate intestinal histology lesions
might not be correctly diagnosed by pathologists with little
experience in CD and cultured EmA assay could reduce the
frequency of false-negative results. We suggest that an
intestinal mucosa culture with gliadin-peptide to assay EmA
in the supernatants should be performed in all cases to help
identify CD patients who have an in ltrative/hyperplastic
picture of intestinal histology. In fact, this histology can also be
found in patients with intestinal giardiasis or food intolerance
(i.e. cow’s milk protein or soy intolerance).
Unfortunately, in the present study, we did not perform the
anti-transglutaminase (anti-tTG) antibodies serum assay in all
our patients and, consequently, are unable to compare the
diagnostic accuracy of cultured EmA determination with that
of the serum anti-tTG, which is generally considered a more
sensitive test than serum EmA (20, 21). However, in the
subgroup of our patients with mild intestinal mucosa lesion,
 ve subjects negative for serum EmA, but positive for
cultured EmA assay, also underwent serum anti-tTG deter-
mination and were negative.
In the present study, all our patients with in ltrative/
hyperplastic lesions—Marsh’s types 1 or 2 (11)—were
symptomatic on a gluten-containing diet, and were cured and
had completely normal intestinal histology on a gluten-free
diet. One of them, a woman, was the mother of a CD child who
on CD diagnosis showed serum EmA positivity (titre >1:400)
and total villous atrophy of the intestinal mucosa. In addition,
all patients showed the classical CD haplotype, DQ2.
Our results also con rm that the intestinal mucosa is the
primary site of EmA production (3) and we hypothesize that
in a quota of CD patients with minimal intestinal lesions EmA
production by the intestinal mucosa would be low and not
suf cient to give serum EmA positivity. This hypothesis is
also in keeping with the results of Biagi et al., who detected
EmA in the organ culture supernatants (without gliadin
stimulation) of CD patients with negative serum EmA and
partial villous atrophy (14). In fact, it has been demonstrated
that in CD patients only the intestinal mucosa-associated
lymphocytes, and not the peripheral blood ones, can produce
anti-transglutaminase antibodies (23).
As regards the possibility that the in vitro challenge in CD
patients on a gluten-free diet may determine EmA production
in the culture medium, the problem arises of the antigen used
in the in vitro system. In fact, Arentz-Hansen et al. recently
demonstrated that only the a9(57–68) and a(62–75) peptides
could stimulate in vitro T-cell response of intestinal lympho-
cytes in adult Norwegian CD patients. However, the
speci city of these peptides might not be absolute, as in
fact they failed to stimulate some intestinal T-cell lines from
Dutch patients (24). Furthermore, previous studies have
identi ed other gliadin peptides active on T lymphocytes in
CD subjects (25, 26). Finally, we underline that our clinical
study is based on B-cell mediated response (humoral
immunity—antibodies production) in the intestinal biopsies
of CD patients and the exact relationship between T- and B-
mucosa lymphocytes in CD pathogenesis is still far from
clear. In this study, we used the a-gliadin 31–43 peptide as the
antigen, a sequence which has been previously demonstrated
as being able to stimulate in vitro EmA production (5).
However, our data showed that only half of the cases were
positive at the in vitro challenge. It is interesting that a
signi cantly higher in ammatory in ltration was found in the
intestinal mucosa of the subjects who were positive at the in
vitro challenge than in the mucosa of those who were
negative; this could indicate that the presence of a threshold
number of memory lymphocytes in the biopsy samples is
necessary to produce EmA in vitro. This hypothesis is also
supported by the shorter duration of the gluten-free diet
observed in the patients who had a positive in vitro challenge
than in those who were negative on challenge. Furthermore,
the real active role of the lymphocyte population in the
cultured biopsy samples is also con rmed in patients with
active CD by the increase of EmA titre in about half of the
samples cultured  rst without the 31–43 peptide and then with
the addition of this peptide. It is dif cult to compare our
results with those of Vogelsang et al., who did not report EmA
production during in vitro challenge in CD on a gluten-free
diet (4), as they used three kinds of gliadin different from the
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31–43 peptide which we used. However, it is important to
underline that our experiments lasted 48 h, whereas those of
the Austrian group lasted only 24 h. Similarly, Biagi et al. did
not evidence EmA production after in vitro gliadin challenge,
but also in this case the experiments lasted 24 h (14). Other
previous data would seem to indicate that this difference is
relevant, since the EmA titre in the culture medium after 48 h
was higher than that recorded after 24 h (3). Furthermore,
experiments lasting up to 72 h showed a positive in vitro
challenge in 11/11 CD patients on a gluten-free diet (5). Other
studies considering both the entity of the in ammatory
in ltration in the biopsy sample and the time of incubation
of the cultured mucosa must be performed on a great number
of CD patients on a gluten-free diet before the determination
of EmA production after in vitro challenge can be considered
a reliable test in con rming CD diagnosis.
In conclusion, our study has shown that EmA assay in the
medium of cultured intestinal biopsy with the addition of
a-gliadin 31–43 can identify gluten-sensitive enteropathies
characterized by an in ltrative/hyperplastic histological
pattern and often associated with negative serum EmA. We
suggest that EmA detection should be performed in cultured
biopsy samples from all patients with negative serology but
with symptoms consistent with a diagnosis of CD.
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